Filing Flows › Mirum Pharmaceuticals (MIRM) › Q2 2026
Mirum Pharmaceuticals (MIRM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Mirum Pharmaceuticals (MIRM) reported revenue of $176M for the second quarter 2026 (Q2 2026), +38% from a year earlier and +10% from the quarter before. Operating margin was -24.1%, net loss $67.2M (38.1% of revenue).
Mirum Pharmaceuticals, Q2 2026: revenue $176M (+38% year over year), operating margin -24.1%, net loss $67.2M, operating cash flow −$44.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $176M | +10% | +38% |
| Operating profit | −$42.5M | — | — |
| Net earnings | −$67.2M | — | — |
| Operating cash flow | −$44.3M | — | -468% |
What changed
Revenue was $176.2M in Q2 2026, up 38% year over year and up 10% from the previous quarter. Livmarli was the largest line at 73% of revenue. Livmarli added $40.6M year over year (up 46%), 84% of the total change.
Operating costs exceeded revenue by $42.5M, an operating margin of -24.1%. Total costs grew 65% against revenue growth of 38%. The fastest-growing cost line was Other operating costs (+100%). The quarter ended with a net loss of $67.2M, narrower than the previous quarter's $790.2M loss.
Operating cash flow was −$44.3M. Non-cash charges added back $6.9M of depreciation and amortization and $30.6M of share-based compensation. Working capital and other items used $14.5M. Capital expenditures of $23K exceeded it, leaving free cash flow of −$44.3M.
Questions
What was Mirum Pharmaceuticals' revenue in the second quarter 2026?
Mirum Pharmaceuticals (MIRM) reported revenue of $176M for the second quarter 2026 (Q2 2026), +38% from a year earlier and +10% from the quarter before.
Was Mirum Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $42.5M (-24.1% of revenue) and net loss $67.2M.